Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjogren's syndrome and systemic lupus erythematosus

Sellam, Jérémie; Miceli‐Richard, Corinne; Gottenberg, Jacques Éric; Ittah, Marc; Lavie, Frédéric; Lacabaratz, Christine; Gestermann, Nicolas; Proust, Alexis; Lambotte, Olivier; Mariette, Xavier

doi:10.1136/ard.2006.065656

Cited by 82 publications

(69 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The aberrant up-regulation of these cytokines may initiate a vicious circle in which enhanced levels of BAFF and APRIL act in an autocrine manner to reinforce the systemic activation of the humoral immune system. Studies have demonstrated that BAFF-R expression is reduced on peripheral B cells of patients with primary pSS and SLE and that decreased BAFF receptor expression on peripheral lymphocytes is associated with increased disease activity in pSS and SLE [40]. We should therefore include antibodies to BAFF-receptor and APRIL in the SLE-specific array.…”

Section: B-cell Markersmentioning

confidence: 99%

Customising an antibody leukocyte capture microarray for systemic lupus erythematosus: Beyond biomarker discovery

Lin

Adelstein

et al. 2010

Proteomics Clinical Apps

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a complex autoimmune disease that has heterogeneous clinical manifestation with diverse patterns of organ involvement, autoantibody profiles and varying degrees of severity of disease. Research and clinical experience indicate that different subtypes of SLE patients will likely benefit from more tailored treatment regimes, but we currently lack a fast and objective test with high enough sensitivity to enable us to perform such sub‐grouping for clinical use. In this article, we review how proteomic technologies could be used as such an objective test. In particular, we extensively review many leukocyte surface markers that are known to have an association with the pathogenesis of SLE, and we discuss how these markers can be used in the further development of a novel SLE‐specific antibody leukocyte capture microarray. In addition, we review some bioinformatics challenges and current methods for using the data generated by these cell‐capture microarrays in clinical use. In a broader context, we hope our experience in developing a disease specific cell‐capture microarray for clinical application can be a guide to other proteomic practitioners who intend to extend their technologies to develop clinical diagnostic and prognostic tests for complex diseases.

show abstract

Section: B-cell Markersmentioning

confidence: 99%

Customising an antibody leukocyte capture microarray for systemic lupus erythematosus: Beyond biomarker discovery

Lin

Adelstein

et al. 2010

Proteomics Clinical Apps

View full text Add to dashboard Cite

show abstract

“…[31][32][33][34] In addition, BAFF-R weak expression could be explained by possible down-regulation of BAFF-R arising from BAFF binding. [35][36][37] EBV activates the NF-B pathway through LMP1 protein, and the link between this activation pathway and lymphomas has also been described. 12,15 As expected, in our series, all 11 NGC DLBCL cases positive for LMP1 were associated with NF-B activation.…”

Section: Discussionmentioning

confidence: 99%

p52 Activation in Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder/Diffuse Large B-Cell Lymphoma without BAFF-R Expression

Proust¹,

Rince²,

Creidy³

et al. 2011

The American Journal of Pathology

View full text Add to dashboard Cite

“…The expression of BAFF-R on peripheral B cells in 20 SjS patients was decreased compared to that in 15 controls and there was no difference in BAFF-R mRNA levels of B cells between SjS patients and controls [98]. On the other hand, in a study of BAFF-R expression in the salivary glands, the expression of BAFF-R on B cells was observed, but the expressions of TACI and BCMA were not [96].…”

Section: Sjögren's Syndromementioning

confidence: 99%

The Roles of the TNF-Family Member B-Cell Activation Factor Belonging to the TNF-Family (BAFF) in Autoimmunity

Hirayama¹,

Nagai²

2017

Immunopathogenesis and Immune-Based Therapy for Selected Autoimmune Disorders

View full text Add to dashboard Cite

The tumor necrosis factor superfamily (TNFSF) member and cytokine known as B-cell activation factor belonging to the TNF-family (BAFF) has been identified as one of the key factors in the selection and survival of B cells. Overexpression of BAFF in mice leads to autoimmunity, whereas BAFF-deficient mice lack mature B cells. Although under normal concentrations of BAFF, non-self-reactive B cells survived and autoreactive B cells were deleted, a higher concentration of BAFF contributed to the survival of autoreactive B cells and elevated autoantibody production. Lupus-prone mice have increased serum levels of BAFF during the onset and progression of disease. The serum BAFF levels are elevated in patients with autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome and ANCA-associated vasculitis, and showed positive correlations with autoantibodies.

show abstract

Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjogren's syndrome and systemic lupus erythematosus

Cited by 82 publications

References 41 publications

Customising an antibody leukocyte capture microarray for systemic lupus erythematosus: Beyond biomarker discovery

Customising an antibody leukocyte capture microarray for systemic lupus erythematosus: Beyond biomarker discovery

p52 Activation in Monomorphic B-Cell Posttransplant Lymphoproliferative Disorder/Diffuse Large B-Cell Lymphoma without BAFF-R Expression

The Roles of the TNF-Family Member B-Cell Activation Factor Belonging to the TNF-Family (BAFF) in Autoimmunity

Contact Info

Product

Resources

About